The effects of the fibrin-derived peptide Bβ15-42 in acute and chronic rodent models of myocardial ischemia-reperfusion

Shock

Volumn 27, Issue 6, 2007, Pages 631-637

  Zacharowski, Kai ^a,f   Zacharowski, Paula A ^a   Friedl, Peter ^b   Mastan, Parissa ^b   Koch, Alexander ^a   Boehm, Olaf ^a   Rother, Russell P ^c   Reingruber, Sonja ^d   Henning, Rainer ^d   Emeis, Jef J ^e   Petzelbauer, Peter ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ALEXION PHARMACEUTICALS   (United States)

^d Fibrex Medical Inc   (Austria)

^e TNO   (Netherlands)

^f BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Fibrin derived peptide; Ischemia reperfusion; Myocardial infarction; Preclinical study centers

Indexed keywords

ASPARTYLARGINYLGLYCYLALANYLPROLYLALANYLHISTIDYLARGINYLPROLYLPROLYL ARGINYLGLYCYLPROLYLISOLEUCYLSERYLGLYCYLARGINYLSERYLTHREONYLPROLYLGLUTAMYLLYSYL GLUTAMYLLYSYLLEUCYLLEUCYLPROLYLGLYCINE; CD18 ANTIGEN; COMPLEMENT COMPONENT C5 INHIBITOR; FIBRIN DERIVATIVE; GLYCYLHISTIDYLARGINYLPROLYLLEUCYLASPARTYLLYSYLLYSYLARGINYLGLUTAMYL GLUTAMINE; GLYCYLHISTIDYLARGINYLPROLYLLEUCYLASPARTYLLYSYLLYSYLARGINYLGLUTAMYL GLUTAMYLALANYLPROLYLSERYLLEUCYLARGINYLPROLYLALANYLPROLYLPROLYLPROLYLISOLEUCYL SERYLGLYCYLGLYCYLGLYCYLTYROSYLARGININE; GLYCYLHISTIDYLARGINYLPROLYLVALYLASPARTYLARGINYLARGINYLLYSYLGLUTAMYL GLUTAMYLPROLYLPROLYLSERYLLEUCYLARGINYLPROLYLALANYLPROLYLPROLYL PROLYLISOLEUCYLSERYLGLYCYLGLYCYLGLYCYLTYROSYLARGININE; PEPTIDE DERIVATIVE; SCAVENGER; TEMPOL; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; ISCHEMIC PRECONDITIONING; LEUKOCYTE MIGRATION; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTIGENS, CD18; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; FIBRINOGEN; FREE RADICAL SCAVENGERS; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIUM; RATS; REPERFUSION INJURY; SPIN LABELS;

EID: 34249013795     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31802fa038     Document Type: Article

References (32)

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, et al.: Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113:e85-e151, 2006.
2. Miller TD, Hodge DO, Sutton JM, Grines CL, O'Keefe JH, DeWood MA, Okada RD, Fletcher WO Jr, Gibbons RJ: Usefulness of technetium-99 m sestamibi infarct size in predicting posthospital mortality following acute myocardial infarction. Am J Cardiol 81:1491-1493, 1998.
3. Frangogiannis NG, Smith CW, Entman ML: The inflammatory response in myocardial infarction. Cardiovasc Res 53:31-47, 2002.
4. Black SC: In vivo models of myocardial ischemia and reperfusion injury: application to drug discovery and evaluation. J Pharmacol Toxicol Methods 43:153-167, 2000.
5. Gross ER, Gross GJ: Ligand triggers of classical preconditioning and postconditioning. Cardiovasc Res 70:212-221, 2006.
6. Kaplan J, O'Connor M, Hake PW, Zingarelli B: Inhibitors of poly (ADP-ribose) polymerase ameliorate myocardial reperfusion injury by modulation of activator protein-1 and neutrophil infiltration. Shock 23:233-238, 2005.
7. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA: Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 95:125-134, 2004.
8. Petzelbauer P, Zacharowski PA, Miyazaki Y, Friedl P, Wickenhauser G, Castellino FJ, Groger M, Wolff K, Zacharowski K: The fibrin-derived peptide B beta(15-42) protects the myocardium against ischemia-reperfusion injury. Nat Med 11:298-304, 2005.
9. Zacharowski K, Zacharowski P, Reingruber S, Petzelbauer P: Fibrin(ogen) and its fragments in the pathophysiology and treatment of myocardial infarction. J Mol Med 84:469-477, 2006.
10. Loike JD, Sodeik B, Cao L, Leucona S, Weitz JI, Detmers PA, Wright SD, Silverstein SC: CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen. Proc Natl Acad Sci U S A 88:1044-1048, 1991.
11. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL: Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 97:2259-2267, 1998.
12. Zacharowski K, Olbrich A, Piper J, Hafner G, Kondo K, Thiemermann C: Selective activation of the prostanoid EP(3) receptor reduces myocardial infarct size in rodents. Arterioscler Thromb Vasc Biol 19:2141-2147, 1999.
13. Zacharowski K, Chatterjee PK, Thiemermann C: Delayed preconditioning induced by lipoteichoic acid from B. subtilis and S. aureus is not blocked by administration of 5-hydroxydecanoate. Shock 17:19-22, 2002.
14. Sivarajah A, McDonald MC, Thiemermann C: The production of hydrogen sulfide limits myocardial ischemia and reperfusion injury and contributes to the cardioprotective effects of preconditioning with endotoxin, but not ischemia in the rat. Shock 26:154-161, 2006.
15. Zacharowski K, Olbrich A, Otto M, Hafner G, Thiemermann C: Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol 126:849-858, 1999.
16. Ploplis VA, Wilberding J, McLennan L, Liang Z, Cornelissen I, Deford ME, Rosen ED, Castellino FJ: A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice. Am J Pathol 157:703-708, 2000.
17. Zacharowski K, Zacharowski PA, Koch A, Baban A, Tran N, Berkels R, Papewalis C, Schulze-Osthoff K, Knuefermann P, Zahringer U, et al.: Toll-like receptor 4 plays a crucial role in the immune-adrenal response to systemic inflammatory response syndrome. Proc Natl Acad Sci U S A 103:6392-6397, 2006.
18. Souza DG, Coutinho SF, Silveira MR, Cara DC, Teixeira MM: Effects of a BLT receptor antagonist on local and remote reperfusion injuries after transient ischemia of the superior mesenteric artery in rats. Eur J Pharmacol 403:121-128, 2000.
19. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124-1136, 1986.
20. Liaw WJ, Chen TH, Lai ZZ, Chen SJ, Chen A, Tzao C, Wu JY, Wu CC: Effects of a membrane-permeable radical scavenger, Tempol, on intraperitoneal sepsis-induced organ injury in rats. Shock 23:88-96, 2005.
21. Gelvan D, Saltman P, Powell SR: Cardiac reperfusion damage prevented by a nitroxide free radical. Proc Natl Acad Sci U S A 88:4680-4684, 1991.
22. McDonald MC, Zacharowski K, Bowes J, Cuzzocrea S, Thiemermann C: Tempol reduces infarct size in rodent models of regional myocardial ischemia and reperfusion. Free Radic Biol Med 27:493-503, 1999.
23. Matsumoto K, Krishna MC, Mitchell JB: Novel pharmacokinetic measurement using electron paramagnetic resonance spectroscopy and simulation of in vivo decay of various nitroxyl spin probes in mouse blood. J Pharmacol Exp Ther 310:1076-1083, 2004.
24. Tanaka M, Brooks SE, Richard VJ, FitzHarris GP, Stoler RC, Jennings RB, Arfors KE, Reimer KA: Effect of anti-CD18 antibody on myocardial neutrophil accumulation and infarct size after ischemia and reperfusion in dogs. Circulation 87:526-535, 1993.
25. Arai M, Lefer DJ, So T, DiPaula A, Aversano T, Becker LC: An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. J Am Coll Cardiol 27:1278-1285, 1996.
26. Dove A: CD18 trials disappoint again. Nat Biotechnol 18:817-818, 2000.
27. Carrier M, Menasche P, Levy JH, Newman MF, Taylor KM, Haverich A, Chen JC, Shernan SK, Van de WF, van der LM, et al.: Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. J Thorac Cardiovasc Surg 131:352-356, 2006.
28. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, et al.: Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 108:1184-1190, 2003.
29. Gorlatov S, Medved L: Interaction of fibrin(ogen) with the endothelial cell receptor VE-cadherin: mapping of the receptor-binding site in the NH2-terminal portions of the fibrin beta chains. Biochemistry 41:4107-4116, 2002.
30. Odrljin TM, Shainoff JR, Lawrence SO, Simpson-Haidaris PJ: Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin beta chain. Blood 88:2050-2061, 1996.
31. Yakovlev S, Gorlatov S, Ingham K, Medved L: Interaction of fibrin(ogen) with heparin: further characterization and localization of the heparin-binding site. Biochemistry 42:7709-7716, 2003.
32. Blancke F, Claeys MJ, Jorens P, Vermeiren G, Bosmans J, Wuyts FL, Vrints CJ: Systemic inflammation and reperfusion injury in patients with acute myocardial infarction. Mediators Inflamm 14:385-389, 2005.